Artios Pharma
Biotech / DNA damage response oncology, Cambridge
Clinical-stage biotech developing DNA damage response cancer therapies. It raised $115m in its Series D+ in November 2025. We can't read its job board yet.
Backed by Janus Henderson Investors, RA Capital, Sofinnova Partners and SV Health Investors.
On the Home Office register of licensed visa sponsors.
Open roles over time
We can't read this company's job board yet.
Hiring momentum
Roles per weekNot tracked yet.
In the news
All 55 stories- OtherIMDb, 9 days ago‘The Pitt,’ ‘Shrinking,’ ‘The Diplomat’ Among Casting Society’s 2027 Artios TV Nominations
- OtherCasting Networks, 24 days agoCongratulations to the 2027 Artios Awards Non-Film Nominees
- OtherBroadway News, 26 days agoCasting directors of ‘Liberation,’ ‘Ragtime,’ ‘Schmigadoon!’ and more nominated for 42nd Artios Awards
- OtherIMDb, 26 days ago‘Heated Rivalry,’ ‘The Pitt,’ ‘Pluribus’ among 2026 Artios Awards nominees: See the full list
- OtherDeadline, 26 days ago2027 Artios Awards Nominations: Casting Society Celebrates TV, Theater & More
- OtherPlaybill, 26 days agoCats: The Jellicle Ball Liberation , More Nominated for Artios Casting Awards; See the Full List of Nominees